Non‑alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)

  • Authors:
    • Cristina Bica
    • Camelia Sandu
    • Andra Iulia Suceveanu
    • Eliza Sarbu
    • Roxana Adriana Stoica
    • Florentina Gherghiceanu
    • Roxana Elena Bohiltea
    • Simona Diana Stefan
    • Anca Pantea Stoian
  • View Affiliations

  • Published online on: June 12, 2020     https://doi.org/10.3892/etm.2020.8882
  • Pages: 2387-2391
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑alcoholic fatty liver disease (NAFLD) has a high prevalence in type 2 diabetes mellitus (T2DM) patients, being one of the disorders with a relevant global burden. Cross‑sectional studies have shown that patients with T2DM and NAFLD have a higher prevalence of liver fibrosis, compared with the general population. Patients with non‑alcoholic steatohepatitis (NASH) and T2DM have an increased mortality and morbidity, therefore they generate substantial health care costs. NASH worsens chronic diabetes complications, and T2DM aggravate the NASH progression to fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). The objectives in NAFLD and NASH therapy are to reduce disease activity, to slow down progression of fibrosis, and to lower the risk factors. Unfortunately, there are no specific validated pharmacological therapies. Several trials have demonstrated that anti‑diabetic agents such as thiazolidindiones, sodium‑glucose co‑transporter inhibitors, glucagon like peptide‑1 receptor analogs, or dipeptidyl peptidase‑4 inhibitors might have complimentary benefits for patients with NAFLD. Some of the effect on reducing steatosis and fibrosis is explained by the weight loss these treatments produce. A goal in standard care is developing screening tools, early and non‑invasive diagnosis methods, studying the pleiotropic effects of drugs, together with newer therapeutic agents, which can target mutual pathogenic mechanisms for diabetes and liver disease.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bica C, Sandu C, Suceveanu AI, Sarbu E, Stoica RA, Gherghiceanu F, Bohiltea RE, Stefan SD and Stoian AP: Non‑alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). Exp Ther Med 20: 2387-2391, 2020
APA
Bica, C., Sandu, C., Suceveanu, A.I., Sarbu, E., Stoica, R.A., Gherghiceanu, F. ... Stoian, A.P. (2020). Non‑alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). Experimental and Therapeutic Medicine, 20, 2387-2391. https://doi.org/10.3892/etm.2020.8882
MLA
Bica, C., Sandu, C., Suceveanu, A. I., Sarbu, E., Stoica, R. A., Gherghiceanu, F., Bohiltea, R. E., Stefan, S. D., Stoian, A. P."Non‑alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)". Experimental and Therapeutic Medicine 20.3 (2020): 2387-2391.
Chicago
Bica, C., Sandu, C., Suceveanu, A. I., Sarbu, E., Stoica, R. A., Gherghiceanu, F., Bohiltea, R. E., Stefan, S. D., Stoian, A. P."Non‑alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)". Experimental and Therapeutic Medicine 20, no. 3 (2020): 2387-2391. https://doi.org/10.3892/etm.2020.8882